54.227.97.219
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
AASLD
Conference Roundup
Lupus Nephritis
SPLIT

New analysis of AURORA 1 Phase 3 study data presented at ERA-EDTA 2021 Congress

Posted on June 7, 2021

Voclosporin (Lupkynis; Mirum) with mycophenolate mofetil (MMF) and low-dose steroids resulted in statistically significant increased renal response rates regardless of the level of urine protein creatinine ratio (UPCR) in patients with lupus nephritis, according to data from an analysis of the Phase 3 AURORA 1 study presented at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress.

First interim results of AURORA 2 continuation study were presented at EULAR 2021 in early June.

“This new look at the data on Lupkynis is significant because it demonstrates the ability of the therapy to deliver meaningful renal response rates at UPCR levels beyond the initial target in its Phase 3 study,” said study co-author, Maria Dall’Era, MD, Director, UCSF Lupus Clinic and Rheumatology Clinical Research Center, Department of Medicine, University of California, San Francisco. “Multiple previous studies have suggested that level of proteinuria represents the best clinical predictor of long-term kidney outcome. Thus, seeing the benefits of Lupkynis even in the most stringent UPCR levels is encouraging for lupus nephritis patients and the physicians treating this challenging condition.”

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-